

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5599186

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
GANYMED PHARMACEUTICALS GMBH	05/27/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BIONTECH SE
<b>Street Address:</b>	AN DER GOLDGRUBE 12
<b>City:</b>	MAINZ
<b>State/Country:</b>	GERMANY
<b>Postal Code:</b>	55131
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Patent Number:</b>	7875424
<b>Patent Number:</b>	9733251
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(312)580-1189
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	312-580-1180
<b>Email:</b>	dkenney@olsonip.com
<b>Correspondent Name:</b>	DOLORES T. KENNEY, OLSON & CEPURITIS, LTD.
<b>Address Line 1:</b>	20 NORTH WACKER DRIVE
<b>Address Line 2:</b>	36TH FLOOR
<b>Address Line 4:</b>	CHICAGO, ILLINOIS 60606
<b>ATTORNEY DOCKET NUMBER:</b>	VOS 203-203.2-165746-2
<b>NAME OF SUBMITTER:</b>	DOLORES T. KENNEY
<b>SIGNATURE:</b>	/Dolores T. Kenney, Reg. No. 31269/
<b>DATE SIGNED:</b>	07/01/2019
<b>Total Attachments: 1</b>	
source=VOS-203-203.2 Patent Assignment#page1.tif	

## Assignment

Ganymed Pharmaceuticals GmbH, having principal offices in Mainz, Germany, for valuable consideration, the receipt and sufficiency of which is hereby acknowledged, hereby sells, assigns and transfers to **BioNTech SE**, a public limited company under European Union Law, having its principal offices at An der Goldgrube 12, 55131 Mainz Germany, its successors and assigns (collectively, the "Assignee"), its entire right, title and interest in and to:

United States Patent No. 7,875,424, issued January 25, 2011

and

United States Patent No. 9,733,251, issued August 15, 2017

both of which are entitled:

"Identification of Tumour-Associated Cell  
Surface Antigens For Diagnosis and Therapy".

the same to be held and enjoyed by said BioNTech SE to the full end of the term for which said U.S. Letters Patent is granted, as fully and entirely as the same could have been held and enjoyed by Ganymed Pharmaceuticals GmbH.

Signed at Mainz, Germany this 27th day of May, 2019.

**Ganymed Pharmaceuticals GmbH**

By: 

[Signature]

Printed Name: Kevin D. Miles

Title: General Manager

By: \_\_\_\_\_

[Signature]

Printed Name: \_\_\_\_\_

Title: \_\_\_\_\_